4.7 Article

Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy

Journal

CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 79, Issue 1, Pages -

Publisher

SPRINGER BASEL AG
DOI: 10.1007/s00018-021-04111-2

Keywords

Retinopathy of prematurity; Secretogranin III; Scg3; Pathological angiogenesis; Physiological angiogenesis; Targeted anti-angiogenic therapy

Funding

  1. NIH [R01EY027749, R24EY028764, R24EY028764-01A1S1, R43EY031238, R43EY031643, R41EY027665, P30EY002520]
  2. American Diabetes Association [1-18-IBS-172]
  3. Knights Templar Eye Foundation Endowment in Ophthalmology
  4. Research to Prevent Blindness (RPB)

Ask authors/readers for more resources

Secretogranin III (Scg3) is a disease-specific angiogenic factor that strictly regulates pathological angiogenesis without affecting physiological angiogenesis. The use of anti-Scg3 humanized antibody Fab (hFab) can effectively inhibit pathological angiogenesis without adverse effects, making it a potential safe and effective disease-targeted anti-angiogenic therapy.
Conventional angiogenic factors, such as vascular endothelial growth factor (VEGF), regulate both pathological and physiological angiogenesis indiscriminately, and their inhibitors may elicit adverse side effects. Secretogranin III (Scg3) was recently reported to be a diabetes-restricted VEGF-independent angiogenic factor, but the disease selectivity of Scg3 in retinopathy of prematurity (ROP), a retinal disease in preterm infants with concurrent pathological and physiological angiogenesis, was not defined. Here, using oxygen-induced retinopathy (OIR) mice, a surrogate model of ROP, we quantified an exclusive binding of Scg3 to diseased versus healthy developing neovessels that contrasted sharply with the ubiquitous binding of VEGF. Functional immunohistochemistry visualized Scg3 binding exclusively to disease-related disorganized retinal neovessels and neovascular tufts, whereas VEGF bound to both disorganized and well-organized neovessels. Homozygous deletion of the Scg3 gene showed undetectable effects on physiological retinal neovascularization but markedly reduced the severity of OIR-induced pathological angiogenesis. Furthermore, anti-Scg3 humanized antibody Fab (hFab) inhibited pathological angiogenesis with similar efficacy to anti-VEGF aflibercept. Aflibercept dose-dependently blocked physiological angiogenesis in neonatal retinas, whereas anti-Scg3 hFab was without adverse effects at any dose and supported a therapeutic window at least 10X wider than that of aflibercept. Therefore, Scg3 stringently regulates pathological but not physiological angiogenesis, and anti-Scg3 hFab satisfies essential criteria for development as a safe and effective disease-targeted anti-angiogenic therapy for ROP.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available